Loading…
Sickle Cell Disease Treatment Centers Act of 2024
Legislative Progress
Introduced
September 25, 2024
Latest Action
September 25, 2024
Primary Sponsor
Chris Van HollenDemocratic(MD)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2024 · fourth_quarter · Health Issues
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Policies related to the social security disability programs
Client expense: Not reported · Firm income: $20,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)
2024 · fourth_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097) FDA guidance impacting hematology
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097)
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Policies related to the social security disability programs; submitted nominees for NASEM sickle cell disease expert panel House and Senate Resolutions Expressing support for September as Sickle Cell Disease Awareness Month (H. Res. 1495/S. Res. 861)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)